This site is intended for US Healthcare Professionals only
CT=Computed Tomography; PET=Positron Emission Tomography; PSA=Prostate-Specific Antigen.
At Blue Earth Diagnostics, we develop and provide PET diagnostic imaging radiopharmaceutical products to inform diagnosis and treatment decisions for patients with recurrent prostate cancer. We stand committed to supporting those parts of life that matter most: health and well-being.
September marks Prostate Cancer Awareness Month, a time for raising awareness and taking action to help fight this serious disease that takes the lives of approximately 33,330 U.S. men each year.1
Blue Earth Diagnostics has a strong commitment in prostate cancer, and we are driven to find innovative imaging solutions for men affected by this disease. We work closely with physicians, healthcare professionals and patients to provide access to PET imaging products that can help guide decisions about patient care. Our initial product, Axumin® (fluciclovine F 18) injection, is FDA-approved for PET imaging of prostate cancer recurrence and widely available across the U.S.
At our core, Blue Earth Diagnostics is all about helping patients. We continue to work tirelessly toward that goal so that more men with recurrent prostate cancer can benefit from informed decision making resulting from advanced diagnostic imaging.
1https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html; accessed August 10, 2020
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Please see Axumin full Prescribing Information.